First Tracks Biotherapeutics - Asset Resilience Ratio
First Tracks Biotherapeutics (TRAX) has an Asset Resilience Ratio of 13.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how First Tracks Biotherapeutics's Asset Resilience Ratio has changed over time. Check First Tracks Biotherapeutics strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down First Tracks Biotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of First Tracks Biotherapeutics.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.99 Million | 13.07% |
| Total Liquid Assets | $37.99 Million | 13.07% |
Asset Resilience Insights
- Moderate Liquidity: First Tracks Biotherapeutics has 13.07% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
First Tracks Biotherapeutics Industry Peers by Asset Resilience Ratio
Compare First Tracks Biotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
ZAI LAB LTD0000006
F:1ZLB |
Biotechnology | 0.91% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
Annual Asset Resilience Ratio for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual Asset Resilience Ratio data for First Tracks Biotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.22% | $73.44 Million | $330.55 Million | -37.14pp |
| 2024-12-31 | 59.36% | $262.29 Million | $441.89 Million | -20.56pp |
| 2023-12-31 | 79.92% | $354.94 Million | $444.11 Million | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more